Literature DB >> 18806901

Diastolic dysfunction: a link between hypertension and heart failure.

Sophie Lalande1, Bruce D Johnson.   

Abstract

Diastolic heart failure is characterized by the symptoms and signs of heart failure, a preserved ejection fraction and abnormal left ventricular (LV) diastolic function caused by a decreased LV compliance and relaxation. The signs and symptoms of diastolic heart failure are indistinguishable from those of heart failure related to systolic dysfunction; therefore, the diagnosis of diastolic heart failure is often one of exclusion. The majority of patients with heart failure and preserved ejection fraction have a history of hypertension. Hypertension induces a compensatory thickening of the ventricular wall in an attempt to normalize wall stress, which results in LV concentric hypertrophy, which in turn decreases LV compliance and LV diastolic filling. There is an abnormal accumulation of fibrillar collagen accompanying the hypertension-induced LV hypertrophy, which is also associated with decreased compliance and LV diastolic dysfunction. There are no specific guidelines for treating diastolic heart failure, but pharmacological treatment should be directed at normalizing blood pressure, promoting regression of LV hypertrophy, preventing tachycardia and treating symptoms of congestion. Preventive strategies directed toward an early and aggressive blood pressure control are likely to offer the greatest promise for reducing the incidence of diastolic heart failure. Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806901      PMCID: PMC2713868          DOI: 10.1358/dot.2008.44.7.1221662

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  75 in total

1.  Heart failure--an epidemic of uncertain proportions.

Authors:  Margaret M Redfield
Journal:  N Engl J Med       Date:  2002-10-31       Impact factor: 91.245

Review 2.  New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function.

Authors:  Michael R Zile; Dirk L Brutsaert
Journal:  Circulation       Date:  2002-03-19       Impact factor: 29.690

3.  Lifetime risk for developing congestive heart failure: the Framingham Heart Study.

Authors:  Donald M Lloyd-Jones; Martin G Larson; Eric P Leip; Alexa Beiser; Ralph B D'Agostino; William B Kannel; Joanne M Murabito; Ramachandran S Vasan; Emelia J Benjamin; Daniel Levy
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

4.  Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.

Authors:  T Nousiainen; E Vanninen; E Jantunen; J Puustinen; J Remes; A Rantala; O Vuolteenaho; J Hartikainen
Journal:  J Intern Med       Date:  2002-03       Impact factor: 8.989

Review 5.  New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment.

Authors:  Michael R Zile; Dirk L Brutsaert
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

6.  Reduced exercise arteriovenous O2 difference in Type 2 diabetes.

Authors:  James C Baldi; James L Aoina; Helen C Oxenham; Warwick Bagg; Robert N Doughty
Journal:  J Appl Physiol (1985)       Date:  2002-11-27

7.  Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk.

Authors:  Paola A Lanfranchi; Virend K Somers; Alberto Braghiroli; Ugo Corra; Ermanno Eleuteri; Pantaleo Giannuzzi
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

8.  Relationship of systolic BP to obstructive sleep apnea in patients with heart failure.

Authors:  Don D Sin; Fabia Fitzgerald; John D Parker; Gary E Newton; Alexander G Logan; John S Floras; T Douglas Bradley
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

9.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  Betaxolol improves the survival rate and changes natriuretic peptide expression in rats with heart failure.

Authors:  Kenichi Watanabe; Wen Juan; Gurusamy Narasimman; Meilei Ma; Mikio Inoue; Yuki Saito; Mir I I Wahed; Mikio Nakazawa; Go Hasegawa; Makoto Naito; Hitoshi Tachikawa; Naohito Tanabe; Makoto Kodama; Yoshifusa Aizawa; Tadashi Yamamoto; Kenichi Yamaguchi; Toshihiro Takahashi
Journal:  J Cardiovasc Pharmacol       Date:  2003-01       Impact factor: 3.105

View more
  24 in total

1.  Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4.

Authors:  Susumu Matsuda; Seiji Umemoto; Koichi Yoshimura; Shinichi Itoh; Tomoaki Murata; Tohru Fukai; Masunori Matsuzaki
Journal:  J Atheroscler Thromb       Date:  2015-03-05       Impact factor: 4.928

2.  Vascular Endothelial Growth Factor Prevents Endothelial-to-Mesenchymal Transition in Hypertrophy.

Authors:  Ben M-W Illigens; Alejandra Casar Berazaluce; Dimitrios Poutias; Robert Gasser; Pedro J Del Nido; Ingeborg Friehs
Journal:  Ann Thorac Surg       Date:  2017-05-05       Impact factor: 4.330

Review 3.  Management of Chronic Heart Failure in Primary Care: What Evidence do we have for Heart Failure with Preserved Systolic Function?

Authors:  As Ramli; B Jackson; Ct Toh; D Ambigga; L Piterman
Journal:  Malays Fam Physician       Date:  2010-08-31

4.  The Effects of gamma-Aminobutyric Acid, Vinegar, and Dried Bonito on Blood Pressure in Normotensive and Mildly or Moderately Hypertensive Volunteers.

Authors:  Hiroko Tanaka; Kenichi Watanabe; Meilei Ma; Masao Hirayama; Takashi Kobayashi; Hiroshi Oyama; Yoshiko Sakaguchi; Mitsuo Kanda; Makoto Kodama; Yoshifusa Aizawa
Journal:  J Clin Biochem Nutr       Date:  2009-06-30       Impact factor: 3.114

5.  The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.

Authors:  Que Liu; Lisa Adams; Anatoly Broyde; Rayne Fernandez; Alain D Baron; David G Parkes
Journal:  Cardiovasc Diabetol       Date:  2010-08-03       Impact factor: 9.951

6.  Blunting of estrogen modulation of cardiac cellular chymase/RAS activity and function in SHR.

Authors:  Sarfaraz Ahmad; Xuming Sun; Marina Lin; Jasmina Varagic; Gisele Zapata-Sudo; Carlos M Ferrario; Leanne Groban; Hao Wang
Journal:  J Cell Physiol       Date:  2017-10-04       Impact factor: 6.384

7.  Reversible cardiac dysfunction in long-standing hypertension may be global variant of stress cardiomyopathy.

Authors:  Anand Chockalingam; Senthil A Kumar
Journal:  BMJ Case Rep       Date:  2018-06-29

8.  In vitro studies of early cardiac remodeling: impact on contraction and calcium handling.

Authors:  Kaylan M Haizlip; Paul M L Janssen
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01

9.  Optimal phase for coronary interpretations and correlation of ejection fraction using late-diastole and end-diastole imaging in cardiac computed tomography angiography: implications for prospective triggering.

Authors:  Hussain Isma'eel; Yasmin S Hamirani; Ramona Mehrinfar; Songshuo Mao; Naser Ahmadi; Vahid Larijani; Subu Nair; Matthew J Budoff
Journal:  Int J Cardiovasc Imaging       Date:  2009-07-25       Impact factor: 2.357

10.  Association of Anemia and Blood Pressure With Novel Markers of Diastolic Function in Pediatric Sickle Cell Disease.

Authors:  Simone Jhaveri; Nadine Choueiter; Deepa Manwani; Saritha Ranabothu; Kerry Morrone; Michael Hafeman; Kimberly Reidy; Frederick Kaskel; Joseph Mahgerefteh
Journal:  J Pediatr Hematol Oncol       Date:  2021-05-01       Impact factor: 1.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.